IGI partners with AbbVie and grants exclusive rights to globally develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China
Veteran healthcare executive to drive international growth, strategic partnerships, and global commercialization of the company's molecular diagnostics portfolio
CEO Stéphane Bancel framed the changes as essential to scaling the business
The company secured new accounts, including ACCESS-PVI trial sites, and aims to strengthen global commercialization efforts
Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Approval for generic Ozempic® in Canada strengthens OneSource’s global CDMO footprint in complex peptide injectable manufacturing
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
Under the proposed terms, Vaximm would secure a $20 million upfront payment, up to $815 million tied to clinical, regulatory, and commercial milestones
The MUSE system offers a minimally invasive solution for treating gastroesophageal reflux disease
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
